Lamivudine News and Research

RSS

FDA reinforces use of Sustiva in first-line HIV combination therapy

Bristol-Myers Squibb has announced that Sustiva® (efavirenz) has received approval from the U.S. Food and Drug Administration to include new long-term virologic and clinical data from BMS Study 006 in its prescribing information.

26 Aug 2004

Liver transplantation outcomes have significantly improved for patients with hepatitis B

Since the early 1990s, therapeutic options for patients undergoing liver transplantation for hepatitis B have evolved to include HBV immune globulin (HBIG) and lamivudine.

9 Aug 2004

Approval of fixed-dose combination treatments for HIV-1 infection

The Food and Drug Administration has announced the approvals of Epzicom (abacavir/lamivudine) and Truvada (tenofovir disoproxil/emtricitabine), two fixed-dose combination treatments for HIV-1 infection.

5 Aug 2004

FDA approves two fixed-dose combination treatments for HIV-1 infection

The Food and Drug Administration has announced approved Epzicom (abacavir/lamivudine) and Truvada (tenofovir disoproxil/emtricitabine), two fixed-dose combination treatments for HIV-1 infection.

2 Aug 2004

Roche files for application with FDA to market hepatitis C medication Pegasys(R) for chronic hepatitis B treatment

Roche announced today the submission of a supplemental new biologics license application (sBLA) with the U.S. Food and Drug Administration to market Pegasys(R) (peginterferon alfa-2a) for the treatment of chronic hepatitis B (CHB).

21 Jul 2004

Four new AIDS medicines added to the World Health Organization prequalification list

Four new AIDS medicines are this week being added to the World Health Organization prequalification list, thus further increasing access to a choice of quality products.

15 Jul 2004

New guidelines for antiretroviral drugs to prevent the transmission of HIV from mothers to their children

The World Health Organization has published new guidelines underlining the effectiveness of antiretroviral drugs to prevent the transmission of HIV from seropositive mothers to their children.

15 Jul 2004

AIDS Healthcare Foundation targets GSK over voluntary licensing of its AIDS drug patents in South Africa

At the international AIDS conference in Bangkok, AIDS Healthcare Foundation hosted a peaceful protest against British multinational pharmaceutical giant GlaxoSmithKline over its voluntary licensing of its AIDS drug patents in South Africa.

13 Jul 2004

GSK and Boehringer Ingelheim to develop treatment for HIV infection specifically for the developing world

GlaxoSmithKline and Boehringer Ingelheim announced today that the companies have signed a letter of intent for an accelerated development programme for a co-package for Combivir® (lamivudine/zidovudine) and Viramune® (nevirapine) for chronic treatment of HIV infection in the developing world.

12 Jul 2004

Comparison of antiretroviral therapies shows that tenofovir DF and stavudine are equally effective

Results from a three year double-blinded trial which compared antiretroviral therapies show that the combination regimens of tenofovir DF and stavudine, are equally effective, though tenofovir DF has more favorable outcomes with respect to cholesterol levels and the nervous system.

11 Jul 2004

Inexpensive generic fixed-dose combined therapies appears the most suitable solution for treating AIDS in developing countries

The development of simple and inexpensive generic fixed-dose combined therapies appears the most suitable solution for making possible this access to treatments in developing countries with meagre resources.

3 Jul 2004

Generic fixed-dose combinations (FDCs) of antiretrovirals are a key factor in access to treatment of HIV/AIDS infection in the developing world

Combination therapy with three generic antiretroviral drugs in a single tablet has been validated for the first time in an open clinical study in a developing country. Follow-up of 60 patients treated in Yaoundé, Cameroon, has demonstrated the excellent efficacy and safety of a generic fixed-dose combination.

2 Jul 2004

Access to HIV antiretroviral therapies in the developing world should be a major world health priority

One of the strategies adopted consists in utilizing combinations of fixed doses of generic antiretrovirals, involving three medicinal drugs of two different classes in the same tablet.

2 Jul 2004

WHO removes two antiretroviral products from the WHO List of prequalified products

The World Health Organization (WHO) removed two antiretroviral products from the WHO List of prequalified products

20 Jun 2004

Weekly cycles of once-daily anti-HIV drugs could reduce cost of HIV treatment

24 May 2004

Weekly cycles of once-daily anti-drugs could reduce cost of HIV treatment

In a small study conducted at the U.S. National Institutes of Health (NIH), researchers have shown that it may be feasible to treat HIV-infected patients with a simple, once-daily regimen of anti-HIV drugs given in pre-planned, 7-day-on, 7-day-off cycles. This approach is known formally as “short-cycle structured intermittent antiretroviral therapy” (SIT) or colloquially as the “7-7” approach.

20 May 2004